Background: Efforts to promote the development of pediatric pharmacotherapy include regulatory frameworks and close collaboration between the US Food and Drug Administration and the European Medicines Agency. We characterized the current status of pediatric clinical trials conducted in the United States by the pharmaceutical industry, focusing on the involvement of the European Union member countries, to clarify the industry perspective. Methods: Data on US pediatric clinical trials were obtained from ClinicalTrials.gov. Binary regression analysis was performed to identify what factors influence the likelihood of involvement of European Union countries. Results: A total of 633 US pediatric clinical trials that met inclusion criteria were extracted and surveyed. Of these, 206 (32.5%) involved a European Union country site(s). The results of binary regression analysis indicated that attribution of industry, phase, disease area, and age of pediatric participants influenced the likelihood of the involvement of European Union countries in US pediatric clinical trials. Relatively complicated or large pediatric clinical trials, such as phase II and III trials and those that included a broad age range of participants, had a significantly greater likelihood of the involvement of European Union countries (P < .05). Conclusion: Our results suggest that (1) the pharmaceutical industry utilizes regulatory frameworks in making business decisions regarding pediatric clinical trials, (2) disease area affects the involvement of European Union countries, and (3) feasibility of clinical trials is mainly concerned by pharmaceutical industry for pediatric drug development. Additional incentives for high marketability may further motivate pharmaceutical industry to develop pediatric drugs.
Introduction
To be performed properly, pharmacotherapy must be based on clinical testing of target patients. The results of clinical trials contribute significantly to the development of use recommendations for drugs. In pediatrics, some drugs are prescribed although they have not been specifically tested on or approved for use in children, and official indications for use in children are not specified on the label. This "off-label" use causes a decrease in efficacy in expected treatment and increases the likelihood of adverse effects. [1] [2] [3] Children are not simply "little adults," and the maturity and functioning of children's organs are variable, increasing the complexity of proper dose conversion for pediatric patients. Drugs developed and approved specifically for use in pediatric patients should be clinically tested in children. Thus, pediatric drug development must be continuously carried out in order to best serve the needs of pediatric patients.
However, there are many obstacles to pediatric drug development. For instance, pediatric drugs are not attractive to the pharmaceutical industry because of the small size of the market. The pediatric population within the range of 0-14 years of age comprises approximately 26.1% of the total world population 4 ; however, the majority of children are healthy. Therefore, the potential market for pediatric therapies is limited. The relatively small size of the pediatric patient population compared with that of the adult patient population leads to another obstacle for pediatric drug development: difficulty enrolling the necessary number of patients for clinical trials. Various ethical and technical issues further complicate the implementation of pediatric clinical trials (PCTs). Our previous research on pediatric drug development highlights the importance of addressing recruitment and eliminating ethical obstacles; facilitating collaboration among industry, government, academia, and community; expanding regulatory supports; and using innovative clinical trial tools. 5 The "therapeutic orphan" situation, in which studies and evidence on therapies for children are lacking, is being addressed as an international issue as well as a regional issue. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Efficacy, Guideline 11, which is currently in step 3 of the Addendum, provides guidance for the pharmaceutical industry as well as regulatory bodies including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 6 Prior to this international activity, the United States had already established legislative frameworks to facilitate PCTs with the FDA Modernization Act of 1997. 7 This act was reauthorized and modified as the Best Pharmaceuticals for Children Act in 2002, and was complemented by the Pediatric Research Equity Act in 2003. 8, 9 This regulatory framework was reauthorized in the FDA Amendments Act in 2007 and was permanently extended by the FDA Safety and Innovation Act in 2012. 10, 11 In the European Union (EU), the Paediatric Regulation came into force in 2007.
12 Both the American and European legislative frameworks use a "carrot and stick" approach that consists of an obligation to conduct PCTs for drug development as well as incentives for the pharmaceutical industry. Basically, an extension for 6-month exclusivity of the drug is provided as a financial incentive; however, additional elongation of extension differs between the United States and the EU. The "stick" side is the obligation to conduct PCTs unless waivered or deferred, and the strictness is also different between the United States and the EU. To enhance pediatric drug development and PCTs on a global scale, the FDA and EMA have held monthly "Pediatric Cluster" teleconferences since August 2007 to discuss ethical and safety issues, feasibility, and designs of PCTs. 13 Egger et al reported that the waiver decisions of PCTs in the 2 regulatory bodies were similar, though they follow similar but distinct legislative frameworks and criteria for judgement, suggesting that they collaborated well. 14 Various governmental efforts to combat the therapeutic orphan status of pediatric medicine have been implemented, and some improvements have resulted. However, pediatric patients remain a therapeutic orphan, and drug development for neonatal patients is particularly lacking. 15 Pediatric drug development is driven by the pharmaceutical industry, which is compelled to make various efforts to solve the therapeutic orphan status problem in conjunction with regulatory bodies. However, there is a lack of information on the factors that govern the industry's decision making with regard to PCTs. Thus, it is important to assess the response of the pharmaceutical industry in order to develop better regulatory initiatives. In this study, we aimed to characterize how the pharmaceutical industry designs and conducts PCTs in the United States, and the factors that influence whether or not these PCTs include sites in EU member countries.
Methods

Data Source and the Analyzed Data Set
We downloaded clinical trial information from the US database ClinicalTrials.gov on June 13, 2016. We extracted clinical trials that started after October 1, 2007, which is when the FDA Amendments Act began requiring applicable interventional clinical trials to register on ClinicalTrials.gov, 10 and before December 31, 2015. We only included clinical trials listed as "completed" or "active, not recruiting," because information of locations could be later changed from the posted information. PCTs were defined as clinical trials in which the midpoint of the eligible age range for enrollment was less than 18 years, as have other reports. 16, 17 Figure 1 provides an overview of the criteria used for extracting PCTs for analysis. The information collected regarding the extracted PCTs includes study status, conditions and interventions being studied, sponsor and collaborators, age eligibility, phase, purpose, design, start and completion dates, and locations of trial centers. Because we focused on the involvement of the EU member countries in US PCTs, we divided the extracted PCTs into 2 categories: PCTs with site(s) in EU countries (PCTwEU) and PCTs without sites in EU countries (PCTwoEU). In this study, we regarded "Europe" as the EU member countries that follow EMA regulations. We performed binary logistic regression analysis to reveal effects of the following factors to whether the pharmaceutical industry decided to involve EU member countries in US PCTs.
Factors Analyzed for Effects on EU Involvement in US PCTs
As the explanatory variables for the binary logistic analysis, we chose the following 5 factors:
1. Attribution of industry: A binary variable indicating whether the sponsors of the trial are listed as member companies on the European Federation of Pharmaceutical Industries and Associations (EFPIA). 18 2. Phase of PCT: An ordinal variable indicating phase I, phase II (including phase I/II), phase III (including phase II/III), or phase IV. 3. Therapeutic area: A categorical variable specifying which of 5 FDA review divisions, discussed within the Pediatric Cluster, relate to the PCT. The categories include oncology, endocrine/metabolic, antivirals, gastroenterology/inborn errors, cardio/renal, and other.
5. Age eligibility of pediatric subjects: A ternary categorical variable with the categories "narrow," "intermediate," and "broad," depending on the age range of the pediatric subjects enrolled in the trial. There are 4 age classes of child: neonates (0-27 days), infants (28 days to 23 months), children (2-11 years), and adolescents (12-17 years). The age range of a PCT was "narrow" if it was allowed to enroll patients from only 1 age class, "intermediate" if it was allowed to enroll patients from 2 age classes, and "broad" if it was allowed to enroll patients in 3 or more age classes.
Statistical Analysis
Binary logistic regression analysis was performed to identify the effects of the 5 explanatory variables described above on whether the US PCTs involve EU countries or not. We set "phase I" in "phase of PCT," "other" in "therapeutic area," and "narrow" in "age eligibility of pediatric subjects" as a comparative base for the analysis. Odds ratio (OR) and 95% confidence interval (CI) were calculated. We also calculated the median and interquartile range (IQR) of the study duration. All statistical analyses and calculations were performed using R (version 3.2.2) and EZR (version 1.32). 20 The significance level was set to a ¼ 0.05.
Results
Our data set consisted of 633 PCTs selected from 30,351 clinical trials identified by the initial search, as shown in Figure 1 . We identified 206 (32.5%) PCTwEU and 427 (67.5%) PCTwoEUs. The median study duration of PCTwEU (2.7 years; IQR, 1.8-4.0 years) was 1.8 times that of PCTwoEU (1.5 years; IQR, 0.8-2.9 years). 95% CI, 2.68-7.08; P < .001), and broad age range (OR, 2.75; 95% CI, 1.51-5.01; P < .001). Table 2 indicates the characteristics of the PCTs in each phase state within each group. There are differences between PCTwEUs and PCTwoEUs in the purpose of phase I trials. In PCTwEUs, pharmacokinetics (PK) or PK/pharmacodynamics (PD) studies were more common (77.3%), while in PCTwoEUs safety, efficacy, or safety/efficacy studies (52.6%) were most common. A similar pattern is apparent with respect to the purpose of phase II and III trials. With respect to the allocation, 40.9% of phase I trials in the PCTwEU group had a randomized study design, but only 13.8% of those in the PCTwoEU group were so. Moreover, 75.0% of phase I PCTwoEUs had a singlegroup study design for the intervention model, while only 50.0% of the PCTwEU group did.
Therapeutic area is compared in Table 3 . PCTwEUs were conducted more often for 4 of 5 areas: the frequencies of trials in the endocrine/metabolic, antivirals, gastroenterology/inborn errors, and cardio/renal areas were 2 or more times higher in PCTwEUs than they were in PCTwoEUs. However, the oncology area was more studied in the PCTwoEU group.
The age classes for pediatric subjects recruited in US PCTs are shown in Table 4 . Overall, age class trends in PCTwEUs and PCTwoEUs were similar.
Discussion
It is important to boost pediatric drug development for resolving the therapeutic orphan status of pediatric patients. The FDA and EMA are cooperating closely and making a variety of efforts in this regard from the perspective of regulatory authorities. One of the efforts is the Pediatric Cluster, which facilitates cooperation between the FDA and the EMA, as well as the Japanese Pharmaceutical and Medical Devices Agency, the Australian Therapeutic Goods Administration, and Health Canada. The purpose of this effort is to ensure that pediatric studies are conducted in a scientifically rigorous and ethical manner and that pediatric patients are not exposed to unnecessary trials. 13 In this study, we analyzed and characterized how the pharmaceutical industry designs and conducts PCTs in the United States, focusing on the involvement of the EU member countries, to better understand how the pharmaceutical industry's pediatric drug development efforts correspond to governmental efforts. For the pharmaceutical industry, PCTwEU may provide an efficient vehicle to obtain clinical data for US-EU drug codevelopment while both avoiding duplicated PCTs and potentially expanding the market size.
We had thought that at least the attribution of pharmaceutical company and targeted therapeutic area would be influential factors for conducting US PCTs together with the EU countries. If the main market of a company is the EU, it is reasonable to involve the EU in the PCT. Companies focused on the pediatric domain and some of rare disease domains need to involve EU countries in their US PCTs because of the small size of the target patient populations, while companies focused on the geriatric domain and more common diseases do not need to do so. The size of the target patient population is also related to age. For example, the rare disease Zellweger syndrome develops in neonatal patients, most of whom do not survive past the first 6 months 21 ; thus, only neonatal patients are appropriate subjects for a Zellweger syndrome PCT. Along with the practical and ethical challenges of conducting PCTs, feasibility of the business model is a major problem for pediatric drug development. Expansion of the market size helps to increase business opportunities.
In this study, we explored 5 explanatory factors that could influence whether or not US PCTs involve EU countries. As expected, EFPIA membership and a focus on rare diseases were identified as significant factors in the likelihood of EU member countries' involvement in US PCTs. The EFPIA represents the pharmaceutical industry operating in Europe. The member companies have their research and development facilities in the EU. Therefore, they might conduct PCTs mainly in the EU, adding US sites to expand the business opportunities that will be available to them after approval of the drug.
The regulatory frameworks for rare disease approval are different in the United States and the EU. Ten-year plus 2-year market exclusivity is granted to a company that develops a pediatric rare disease drug in the EU. 22 The EU's Paediatric Regulation requires PCTs for the approval of therapies targeting pediatric rare diseases.
12 On the contrary, in the United States, the flat sum of 7-year market exclusivity is granted as Orphan Drug Exclusivity. 23 Moreover, the US Pediatric Research Equity Act waives the requirement to conduct PCTs for rare disease drug development. 9 If pharmaceutical companies try to develop rare disease drugs in the EU, it would be advantageous to conduct EU PCTs with US sites in order to enroll the necessary number of patients and to support an efficient and rational business model. Trial phase was also identified as a significant factor in the likelihood of EU member countries' involvement in US PCTs. Phase II and III clinical trials are classified as confirmatory studies examining efficacy and safety in target patient populations, and large sample sizes are often required. Sometimes when conducting these PCTs, recruiting enough pediatric subjects only in the United States is difficult because of the limited number of pediatric patients. We found that majority of phase I PCTwEU adopted randomized study design. Moreover, the purpose of 75% of phase I PCTwEU was to acquire PK or PK/PD data. These results suggest that pharmaceutical companies selected a strategy that could avoid conducting unnecessary PCTs by extrapolating adolescent and/or adult clinical data. As described above, the FDA and EMA are working together to boost pediatric drug development while avoiding unnecessary PCTs. These efforts appear to have had an effect on the strategies of pharmaceutical companies.
Therapeutic area was classified based on the top 5 discussed areas in the Pediatric Cluster. As shown in Table 1 , oncology was identified as a significant factor for the unlikelihood of EU member countries' involvement in US PCTs. We suspect that the severity and fatality of pediatric cancer explains this result. Many pediatric cancer patients and their families wish to participate in PCTs, regardless of the outcome of previous trials of that same drug. In other words, the severity and fatality of pediatric cancer makes it easier to enroll enough participants to conduct a PCT. Moreover, the FDA often applies regulatory advantages such as accelerated approval and/or breakthrough therapy to the fatal disease areas. Thus, the pharmaceutical industry might be able to conduct PCTs in this therapeutic area without involving EU member countries. On the contrary, antivirals and gastroenterology/inborn errors were identified as significant factors of the likelihood of EU member countries' involvement in US PCTs. Safety and efficacy normally differ based on ethnicity. However, the pharmacological target of antivirals is virus itself, and thus, regional differences between the US and the EU can be considered less important. Diseases classified as inborn errors are mainly caused by congenital genetic abnormalities. Drug targets for inborn errors, such as levels of disease-related proteins, are common between the United States and the EU. Moreover, some genetic abnormalities are higher in the Caucasian population than they are in people of other ethnicities. 24, 25 It has been reported that the prevalence of gastroenterological disease is high in both the United States and the EU. 26, 27 Thus, involving EU member countries in US PCTs is desirable in terms of feasibility to recruit sufficient enrollment. These results suggest that the characteristics of the disease area are a stronger influential factor for conducting PCTwEU than are current regulatory activities such as those of the Pediatric Cluster.
The definition of a child includes individuals from neonates to adolescents, and thus body weight differences among pediatric patients vary by an order of magnitude, and the maturity of each organ varies according to patient age and body size. These factors make the operation of PCTs harder in a practical way because a multidosage form considering PK and/or PD is required. Ethical issues are also a key factor for the operation of PCTs. Age of children is the most important factor impacting children's competence to consent to participate in PCTs. 28 Therefore, the complexity of conducting PCTs is dependent on the age range to be enrolled. Our results showed that including a broad combination of age categories was a significant factor in the likelihood of EU member countries' involvement in US PCTs. The frequency of each combination of age category, including "neonate" and "broad," was 1.7 times higher in PCTwEU than it was in 29 Regulatory activities in the EU might have influenced this result. The FDA has also strengthened the regulatory framework for drug development in the FDA Safety and Innovation Act, such that, theoretically, explanation is required if a PCT excludes neonate patients in the FDA written request. 11 This regulatory activity might have affected the similar rate of the neonate age category in narrow age-range PCTwoEU compared with PCTwEU.
High marketability of the drug and feasibility of the development must come together to truly motivate pharmaceutical companies for pediatric drug development. The strategy of drug development in pharmaceutical companies is changing from a "blockbusters" business model to a "niche busters" strategy in the orphan drug space. 30, 31 Thus, if the probability of successful drug development is high and sufficient profit can be expected despite the small market size as a result of effective incentives by government, then investment on the part of the pharmaceutical industry will pay off. Proper incentives may be a crucial factor in improving the current status of pediatric drug development by pharmaceutical companies.
This study has a few limitations. Since the information on ClinicalTrials.gov depends on registrants, missing and vague data exist in our analysis. Thus, careful attention must be paid to interpreting the results. We could not distinguish the main location of the analyzed PCT. Therefore, the main location of PCT is not always the United States. We also could not exclude the possibility that a certain sponsor of a PCT was actually not an active participant in the PCT. Furthermore, we could not distinguish the role of the pharmaceutical company in the clinical trial, a sponsor, and a collaborator. The degree of contribution by companies was uncertain from the data set on ClinicalTrials.gov. Besides, 88% of analyzed PCTs were conducted by pharmaceutical companies as sponsors. Nevertheless, our results indicated certain aspects of current pharmaceutical industry conducting PCTs in the United States corresponding to regulatory activities.
Conclusion
The problem of the therapeutic orphan status of pediatric pharmacotherapy should be solved to meet the needs of pediatric patients. Pharmaceutical companies, regulatory bodies, and governments are working on this problem in many ways. Our results reveal that pharmaceutical companies utilize regulatory frameworks to meet their business opportunities. Although further investigations that address the affordability of health care, social security, and health economics are necessary to draw a conclusion, additional incentives for high marketability may further motivate pharmaceutical industry to develop pediatric drugs.
